Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.

about

Update on relapsed ovarian cancer treatment: from new consensus to daily clinical practice.

Item

http://www.wikidata.org/entity/Q47903356

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Update on relapsed ovarian can ...... us to daily clinical practice.

@en

Update on relapsed ovarian can ...... us to daily clinical practice.

@nl

type

Item

label

Update on relapsed ovarian can ...... us to daily clinical practice.

@en

Update on relapsed ovarian can ...... us to daily clinical practice.

@nl

prefLabel

Update on relapsed ovarian can ...... us to daily clinical practice.

@en

Update on relapsed ovarian can ...... us to daily clinical practice.

@nl

P1476

Update on relapsed ovarian can ...... us to daily clinical practice.

@en

P2093

Antonio González-Martín

http://www.w3.org/2001/XMLSchema#string

P2860

Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.

Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

P304

3-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2017-0316

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

23s

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29020819

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer